BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26848258)

  • 1. Dose comparison of conivaptan (Vaprisol®) in patients with euvolemic or hypervolemic hyponatremia--efficacy, safety, and pharmacokinetics.
    Palmer BF; Rock AD; Woodward EJ
    Drug Des Devel Ther; 2016; 10():339-51. PubMed ID: 26848258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
    Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
    Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL; Stalker D; Keirns J
    Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia.
    Annane D; Decaux G; Smith N;
    Am J Med Sci; 2009 Jan; 337(1):28-36. PubMed ID: 19057376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
    Ghali JK; Koren MJ; Taylor JR; Brooks-Asplund E; Fan K; Long WA; Smith N
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2145-52. PubMed ID: 16522696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.
    Koren MJ; Hamad A; Klasen S; Abeyratne A; McNutt BE; Kalra S
    Am J Health Syst Pharm; 2011 May; 68(9):818-27. PubMed ID: 21515866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous conivaptan.
    Moen MD; Keating GM
    Am J Cardiovasc Drugs; 2008; 8(5):341-8; discussion 349. PubMed ID: 18828645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia.
    Kalra S; Efrati S; Arthur JM; Oliven A; Velez JC; McNutt BE; Klasen S; Abeyratne A
    Am J Health Syst Pharm; 2011 Apr; 68(7):590-8. PubMed ID: 21411800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conivaptan for hyponatremia in the neurocritical care unit.
    Wright WL; Asbury WH; Gilmore JL; Samuels OB
    Neurocrit Care; 2009; 11(1):6-13. PubMed ID: 19003543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effect of conivaptan bolus dosing in hyponatremic neurosurgical patients.
    Marik PE; Rivera R
    Pharmacotherapy; 2013 Jan; 33(1):51-5. PubMed ID: 23307545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study.
    Verbalis JG; Zeltser D; Smith N; Barve A; Andoh M
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):159-68. PubMed ID: 18034777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
    Der-Nigoghossian C; Lesch C; Berger K
    Pharmacotherapy; 2017 May; 37(5):528-534. PubMed ID: 28295447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
    Vaghasiya RP; DeVita MV; Michelis MF
    Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observations regarding the use of the aquaretic agent conivaptan for treatment of hyponatremia.
    Metzger BL; DeVita MV; Michelis MF
    Int Urol Nephrol; 2008; 40(3):725-30. PubMed ID: 18363040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
    J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
    Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
    Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit.
    Murphy T; Dhar R; Diringer M
    Neurocrit Care; 2009; 11(1):14-9. PubMed ID: 19123060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
    Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion.
    Potts MB; DeGiacomo AF; Deragopian L; Blevins LS
    Neurosurgery; 2011 Aug; 69(2):268-73. PubMed ID: 21792136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conivaptan: new treatment for hyponatremia.
    Walter KA
    Am J Health Syst Pharm; 2007 Jul; 64(13):1385-95. PubMed ID: 17592003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.